Perfluorododecanoic acid (Synonyms: PFDoA)

Cat. No.: HY-W275295 Purity: 95%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Perfluorododecanoic acid (PFDoA) is an orally active, blood-brain barrier-permeable perfluorinated compound. Perfluorododecanoic acid increases Caspase 3 activity, disrupts mitochondrial membrane potential, and elevates ROS levels. Perfluorododecanoic acid induces cognitive deficits. Perfluorododecanoic acid exhibits hepatotoxicity.

For research use only. We do not sell to patients.

Perfluorododecanoic acid Chemical Structure

CAS No. : 307-55-1

Size	Stock	Quantity
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

Caspase 3

In Vitro

Perfluorododecanoic acid (25-100 μM; 24 h) reduces the viability of PC12 cells in a dose-dependent manner^[2].
Perfluorododecanoic acid (50-100 μM) induces oxidative stress in PC12 cells and significantly increases the levels of ROS and MDA^[2].
Perfluorododecanoic acid (50-100 μM) disrupts the mitochondrial membrane potential of PC12 cells, resulting in a significant reduction in membrane potential^[2].
Perfluorododecanoic acid (100 μM) activates Caspase 3 in PC12 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	PC12
Concentration:	25 μM, 50 μM, 100 μM
Incubation Time:	24 h
Result:	Decreased PC12 cell viability in a dose-dependent manner. Decreased cell viability by 1.23-fold (p < 0.05) at 50 μM. Decreased cell viability by 1.39-fold (p < 0.05) at 100 μM.

In Vivo

Perfluorododecanoic acid (20-80 μg/g body weight; i.p.; single injection) induces dose- and time-dependent hepatotoxicity in female zebrafish, characterized by histopathological liver damage, oxidative stress, and disrupted transcription of genes involved in fatty acid oxidation and antioxidation, with the 80 μg/g dose causing the most severe effects including a 7-fold increase in hepatic lipid peroxidation at 7 days post-injection^[1].
Perfluorododecanoic acid (5-50 mg/kg; p.o.; single dose) accumulates in the brain of adult male Wistar rats after a single oral dose, inducing dose-dependent cognitive deficit that persists for at least 30 days and increasing time spent in open arms in the elevated-plus maze test at 50 mg/kg^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Danio rerio (adult female)^[1]
Dosage:	20 μg/g body weight; 40 μg/g body weight; 80 μg/g body weight
Administration:	i.p.; single injection
Result:	Caused hepatocyte swelling at 7 days post-injection (20 μg/g dose). Caused obscured cell borders and vacuolar degeneration at 7 days post-injection (40 μg/g dose). Caused severe hepatic lesions including nuclei enlargement, pycnosis, hepatocyte necrosis, cytolysis, and near-collapse of cellular structure at 7 days post-injection (80 μg/g dose). Induced dose-dependent decreases in GSH content of 14%, 26%, 29% respectively at 48 h post-injection. Caused 14% and 12% decreases in GSH content at 96 h post-injection (20 μg/g and 80 μg/g doses respectively). Caused significant depletion of GSH content at 7 days post-injection (80 μg/g dose). Caused significant decreases in SOD activity at 48 h post-injection (all doses). Caused significant elevations in SOD activity compared to controls at 7 days post-injection (40 μg/g and 80 μg/g doses). Showed time-related increases in SOD activity across all doses at 96 h and 7 days relative to 48 h. Caused significant decreases in CAT activity at 48 h post-injection (all doses). Caused a significant 1.4-fold reduction in CAT activity at 96 h post-injection (20 μg/g dose). Induced significant dose-dependent increase in GPx activity at 48 h post-injection. Caused a significant 1.6-fold increase in GPx activity at 7 days post-injection (80 μg/g dose). Showed significantly decreased GPx activity at 7 days relative to 48 h (all doses). Caused a significant 7-fold increase in hepatic lipid peroxidation (MDA) at 7 days post-injection (80 μg/g dose). Caused a significant 2.8-fold decrease in L-FABP gene expression at 7 days post-injection (20 μg/g dose). Induced dose-dependent significant decreases in PPARα gene expression of 1.6-fold, 2.2-fold, 2.5-fold respectively at 7 days post-injection. Caused significant decreases in CPT-I gene expression of 2.0-fold, 1.6-fold, 2.2-fold respectively at 7 days post-injection. Caused a significant 2.0-fold induction in MCAD gene expression at 7 days post-injection (40 μg/g dose); caused an elevation in MCAD gene expression at 7 days post-injection (80 μg/g dose). Induced dose-dependent significant decreases in UCP-2 gene expression of 1.5-fold, 2.0-fold, 2.3-fold respectively at 7 days post-injection. Caused significant decreases in Bcl-2 gene expression of 1.8-fold, 1.6-fold, 2.1-fold respectively at 7 days post-injection.

Animal Model:	Wistar (male, 8 weeks old)^[3]
Dosage:	5 mg/kg; 20 mg/kg; 50 mg/kg
Administration:	p.o.; single dose
Result:	Reached a brain concentration of 44.4 μg/g tissue and serum concentration of 24.4 μg/mL 9 days post-dosing at 50 mg/kg. Reached a brain concentration of 28.6 μg/g tissue 30 days post-dosing at 50 mg/kg. Induced a significant decrease in discrimination index at doses ≥20 mg/kg on Days 6-7 post-dosing. Caused a persistent discrimination index deficit through Day 30 post-dosing at 50 mg/kg, with no change in total exploration time at any dose or time point. Triggered a decrease in discrimination index when brain concentrations exceeded 20 μg/g tissue. Significantly increased time spent in open arms at 50 mg/kg, with no changes in distance traveled, total arm entries, or percentage of open arm entries. Showed no significant differences in alternation percentage, total arm entries, distance traveled, number of crossings, time spent in the central area, or immobility time between 50 mg/kg and vehicle-treated rats.

Molecular Weight

614.10

Formula

C₁₂HF₂₃O₂

CAS No.

307-55-1

Appearance

Solid

Color

White to off-white

SMILES

C(=O)(C(C(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 5.83 mg/mL (9.49 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6284 mL	8.1420 mL	16.2840 mL
5 mM	0.3257 mL	1.6284 mL	3.2568 mL
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 95%

Select Batch:

Data Sheet (279 KB) SDS (640 KB)

COA (246 KB) HNMR (259 KB) CNMR (276 KB) MS (71 KB)

Handling Instructions (2659 KB)

References

[1]. Liu Y, et al. Induction of time-dependent oxidative stress and related transcriptional effects of perfluorododecanoic acid in zebrafish liver. Aquat Toxicol. 2008;89(4):242-250. [Content Brief]

[2]. Fang X, et al. Oxidative stress and mitochondrial membrane potential are involved in the cytotoxicity of perfluorododecanoic acid to neurons. Toxicol Ind Health. 2020;36(11):892-897.

[3]. Kawabata K, et al. Perfluorododecanoic Acid Induces Cognitive Deficit in Adult Rats. Toxicol Sci. 2017;157(2):421-428.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6284 mL	8.1420 mL	16.2840 mL	40.7100 mL
DMSO	5 mM	0.3257 mL	1.6284 mL	3.2568 mL	8.1420 mL

Perfluorododecanoic acid Related Classifications

Neurological Disease Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Perfluorododecanoic acid307-55-1PFDoAReactive Oxygen Species (ROS)CaspaseMitochondrial Metabolismfemale zebrafishuncoupling protein 2adult male Wistar ratsperoxisome proliferating activating receptor βliver fatty acid binding proteinBcl-2medium-chain fatty acid dehydrogenasecarnitine palmitoyl-transferase Icaspase 3PC12 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *